caa a22 4500 463251105 CHVBK 20180405153340.0 cr unu---uuuuu 170326e20070201xx s 000 0 eng 10.1007/s10803-006-0234-7 doi (NATIONALLICENCE)springer-10.1007/s10803-006-0234-7 Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial [Elektronische Daten] [Gahan Pandina, Cynthia Bossie, Eriene Youssef, Young Zhu, Fiona Dunbar] Subgroup analysis of children (5-12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders. The primary efficacy measure was the Aberrant Behavior Checklist-Irritability (ABC-I) subscale. Data were available for 55 children given risperidone (n=27) or placebo (n=28); mean baseline ABC-I (±SD) was 20.6 (8.1) and 21.6 (10.2). Risperidone [mean dose (±SD): 1.37mg/day (0.7)] resulted in significantly greater reduction from baseline to endpoint in ABC-I versus placebo [mean change (±SD): −13.4 (1.5) vs. −7.2 (1.4), P<0.05; ES=−0.7]. The most common adverse effect with risperidone was somnolence (74% vs. 7% with placebo). Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism. Springer Science+Business Media, LLC, 2006 Autism nationallicence Risperidone nationallicence Behavioral symptoms nationallicence Hyperactivity nationallicence Irritability nationallicence Safety nationallicence Pandina Gahan Medical Affairs, Janssen Pharmaceutica, Inc., Titusville, NJ, USA aut Bossie Cynthia Medical Affairs, Janssen Pharmaceutica, Inc., Titusville, NJ, USA aut Youssef Eriene Medical Affairs, Janssen Pharmaceutica, Inc., Titusville, NJ, USA aut Zhu Young Medical Affairs, Janssen Pharmaceutica, Inc., Titusville, NJ, USA aut Dunbar Fiona Janssen-Ortho, Inc., Toronto, ON, Canada aut Journal of Autism and Developmental Disorders Kluwer Academic Publishers-Plenum Publishers; http://www.springer-ny.com 37/2(2007-02-01), 367-373 0162-3257 37:2<367 2007 37 10803 https://doi.org/10.1007/s10803-006-0234-7 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10803-006-0234-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Pandina Gahan Medical Affairs, Janssen Pharmaceutica, Inc., Titusville, NJ, USA aut NATIONALLICENCE 700 1- Bossie Cynthia Medical Affairs, Janssen Pharmaceutica, Inc., Titusville, NJ, USA aut NATIONALLICENCE 700 1- Youssef Eriene Medical Affairs, Janssen Pharmaceutica, Inc., Titusville, NJ, USA aut NATIONALLICENCE 700 1- Zhu Young Medical Affairs, Janssen Pharmaceutica, Inc., Titusville, NJ, USA aut NATIONALLICENCE 700 1- Dunbar Fiona Janssen-Ortho, Inc., Toronto, ON, Canada aut NATIONALLICENCE 773 0- Journal of Autism and Developmental Disorders Kluwer Academic Publishers-Plenum Publishers; http://www.springer-ny.com 37/2(2007-02-01), 367-373 0162-3257 37:2<367 2007 37 10803 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer